News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2014

Epigenomics AG: Clinical study conducted in the Czech Republic confirms blood-based Septin9 test to be an attractive alternative for CRC screening programs

PDF 95 KB Study conducted using Epigenomics’ Epi proColon® 2.0 CE Results in line with the results achieved in the CE marking study reported in 2011 Patient convenience might help to increase early colorectal cancer (CRC) detection especially with non-compliant individuals

Read more

Epigenomics AG Reports Preliminary Results and Highlights for the Year Ended December 31, 2013

PDF 105 KB Revenue improved by 53% to EUR 1.6 million (2012: EUR 1.0 million) Net loss reduced by 39% to EUR 7.4 million (2012: EUR 12.2 million) through cost reductions; cash consumption of EUR 6.5 million reduced by 40% (2012: EUR 10.9 million) Decisive steps forward in PMA application of Epi proColon®; FDA advisory […]

Read more

Epigenomics Further Strengthens Intellectual Property Coverage for Epi proColon in the U.S. and in China

PDF 74 KB Patents cover detection of colorectal cancer with Septin9 biomarker Berlin (Germany) and Germantown, MD (U.S.A.) – Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company was granted key Intellectual Property (IP) rights related to its blood-based colorectal cancer screening test Epi proColon® […]

Read more

Epigenomics announces Date for the FDA Advisory Committee Meeting to Review Epi proColon and for the Publication of Preliminary Financial Results 2013

PDF 115 KB Berlin (Germany) and Germantown, MD (U.S.A.), February 06, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), the German-American cancer molecular diagnostics company, today announced that the date for the FDA Advisory Committee meeting for Epigenomics’ blood-based colorectal cancer screening test Epi proColon® was published publicly via a Federal Register notification.

Read more

Epigenomics Begins Trading on OTCQX Marketplace in the U.S.

PDF 129 KB BNY Mellon to act as Principal American Liaison (PAL) for Epigenomics on OTCQX Epigenomics’ ADRs to start trading under ticker symbol EPGNY today Berlin, Germany, and Germantown, MD, U.S.A., January 10, 2014 – Epigenomics AG (Frankfurt Prime Standard: ECX; OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that the Company […]

Read more

Epigenomics signs licensing and supply agreement with Kindstar for Epi proLung in China

PDF 125 KB Berlin, Germany, Germantown, MD, U.S.A. and Wuhan and Beijing, China – Epigenomics AG (Frankfurt Prime Standard: ECX, OTC: EPGNY), a German-American cancer molecular diagnostics company, and Wuhan Kindstar Clinical Diagnostics Co. Ltd (Kindstar), a leading Chinese clinical diagnostics company, announced today that both parties entered into a licensing and supply agreement for […]

Read more